|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C12N 15/113 | (2010.01) |
| A61K 31/7088 | (2006.01) | ||
| A61P 31/14 | (2006.01) |
| (11) | Number of the document | 3505528 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19155538.2 |
| Date of filing the European patent application | 2012-04-20 | |
| (97) | Date of publication of the European application | 2019-07-03 |
| (45) | Date of publication and mention of the grant of the patent | 2020-11-25 |
| (46) | Date of publication of the claims translation | 2021-04-26 |
| (30) | Number | Date | Country code |
| 201161478040 P | 2011-04-21 | US | |
| 201161478038 P | 2011-04-24 | US | |
| 201261596692 P | 2012-02-08 | US | |
| 201261596690 P | 2012-02-08 | US |
| (72) |
SWAYZE, Eric E., US
FREIER, Susan M., US
MCCALEB, Michael L., US
|
| (73) |
Glaxo Group Limited,
980 Great West Road, Brentford, Middlesex TW8 9GS,
GB
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Hepatito B viruso (HBV) raiškos moduliacija |
| MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION |
| Payment date | Validity (years) | Amount | |
| 2025-03-19 | 14 | 289.00 EUR |
| 2026-04-20 |